You have accessJournal of UrologyProstate Cancer: Localized: Surgical Therapy III1 Apr 2018MP16-08 REVO-I® SURGICAL ROBOTIC SYSTEM: RESULTS OF KOREAN FDA (KFDA) APPROVED CLINICAL TRIAL Ki Don Chang, Ali abdel Raheem, Tariq Abdulaziz Alomair, Hyun Kyu Ahn, and Koon Ho Rha Ki Don ChangKi Don Chang More articles by this author , Ali abdel RaheemAli abdel Raheem More articles by this author , Tariq Abdulaziz AlomairTariq Abdulaziz Alomair More articles by this author , Hyun Kyu AhnHyun Kyu Ahn More articles by this author , and Koon Ho RhaKoon Ho Rha More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.542AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES This is the first study of radical prostatectomy using Revo-i® robotic surgical system (Model MSR-5000, meerecompanyInc, Yongin, and Republic of Korea) system in human. METHODS After approval of the Korean Food and Drug Administration for using Revo-i® in human (Number: 814-2016-04-26), a prospective study was carried out on 17 male patients with clinically localized prostate cancer (PCA) using with Revo-i®. RESULTS Mean patient’s age was 69 years old. Mean Operative time (min), docking time (min), console time (min), EBL (ml), and urethrovesical anastomosis time (min) were 180.7±36.8, 9.6±4.6, 108.8±29.1, and 321.3±332.2 and 28.4±8.1 minutes, respectively. No intraoperative organ injury was observed. One patient received blood, intraoperatively. Postoperatively, two patients (12.6%) received blood transfusion (Clavien-Dindo classification 1), and there were no other serious complications (Clavien-Dindo classification =3). The mean hospital stay was 5.2±2 days. A subgroup comparative analysis between PCa patients who underwent either Revo-i® (n=17) or da Vinci (n=17) showing longer console time (106.9±29.3 min vs 77.3±15.5 min, p<0.001) in the Revo-i® group, while both groups had comparable intra- and perioperative findings. CONCLUSIONS The first clinical trial in treating patients with radical prostatectomy using Revo-i® robotic surgical system was performed safely regarding intraoperative and perioperative outcomes. And this surgical system got the approval of commercial usage from Korean government in august 2017. This emergence of new robotic surgical system can make lower cost of expense in applying robotic surgical systems and introduce the development of robotic surgical technology. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e200 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Ki Don Chang More articles by this author Ali abdel Raheem More articles by this author Tariq Abdulaziz Alomair More articles by this author Hyun Kyu Ahn More articles by this author Koon Ho Rha More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...